JNJ Trading 40.1% Above Intrinsic Value Despite Strong Dividend Stream

Johnson & Johnson (JNJ) announced positive phase 3 trial results for its bipolar I disorder drug Caplyta, showing significant efficacy in reducing manic symptoms. The company's strong healthcare portfolio and solid financial health support a sustainable dividend stream despite the stock trading at a premium.

The current dividend yield is 1.93%, with a moderate payout ratio of 50% and a 3-year compound annual growth rate of 4.9%. JNJ's operating margin expansion and predictable revenue growth further support the dividend's safety.

The company holds a strong GF Score of 80/100, driven by strengths in financial stability and profitability, though tempered by valuation and momentum factors. The stock is trading at $271.24, which is 40.1% above its intrinsic GF Value of $193.54.